Physician profile
John P Kolnik
NPI 1902894496
$33,616.90
in general payments reported to CMS, 2019-2025
34 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $1,395 · 2021: $1,293 · 2022: $526 · 2023: $1,293 · 2024: $654 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.06 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $23,456.98 | 2019 | |
| Allergan, INC. | $3,032.52 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,585.55 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,628.73 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $490.37 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $433.81 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Ucb, INC. | $255.53 | 2019-2020 | |
| Qol Medical, LLC | $234.02 | 2019-2024 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $220.95 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $187.85 | 2024-2025 | Voquezna |
| Pfizer INC. | $163.99 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $102.64 | 2020-2023 | Linzess |
| Gilead Sciences, INC. | $76.45 | 2020-2024 | |
| Braintree Laboratories, INC. | $74.21 | 2023-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $70.40 | 2019-2024 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.30 | 2019-2021 | |
| Celgene Corporation | $63.02 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $55.59 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $55.15 | 2022-2023 | Cimzia, Rebyota |
| Regeneron Healthcare Solutions, INC. | $49.64 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $49.17 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
| Evoke Pharma, INC. | $40.15 | 2021-2023 | Gimoti |
| Lilly USA, LLC | $27.95 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $19.01 | 2025 | Zenpep |
| Mylan Institutional INC. | $17.36 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2023 | Cyltezo |
| Ge Healthcare | $16.82 | 2025 | |
| Alfasigma USA, INC. | $14.93 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.89 | 2025 | Sutab |
| Concordia Pharmaceuticals INC. | $14.37 | 2019 | |
| Genzyme Corporation | $14.29 | 2023 | |
| Shire North American Group INC | $14.21 | 2019 | |
| Organon LLC | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kolnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.